These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

808 related items for PubMed ID: 9020325

  • 21. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine.
    Taler SJ, Textor SC, Canzanello VJ, Schwartz L, Porayko M, Wiesner RH, Krom RA.
    Transplantation; 1996 Dec 15; 62(11):1588-92. PubMed ID: 8970613
    [Abstract] [Full Text] [Related]

  • 22. A cyclosporine-based immunosuppressive regimen may be better than tacrolimus for long-term liver allograft survival in recipients transplanted for hepatitis C.
    Rayhill SC, Barbeito R, Katz D, Voigt M, Labrecque D, Kirby P, Miller R, Stolpen A, Wu Y, Schmidt W.
    Transplant Proc; 2006 Dec 15; 38(10):3625-8. PubMed ID: 17175350
    [Abstract] [Full Text] [Related]

  • 23. Immunosuppression with calcineurin inhibitors and polyclonal antibodies in liver transplantation.
    Rafecas A, Lladó L, Albiol MT, Ramos E, Torras J, Fabregat J, Lama C, Busquets J, Ibáñez L, Figueras J, Jaurrieta E.
    Transplant Proc; 2002 Feb 15; 34(1):107. PubMed ID: 11959209
    [No Abstract] [Full Text] [Related]

  • 24. Immunosuppression switch in pediatric heart transplant recipients: cyclosporine to FK 506.
    Swenson JM, Fricker FJ, Armitage JM.
    J Am Coll Cardiol; 1995 Apr 15; 25(5):1183-8. PubMed ID: 7534779
    [Abstract] [Full Text] [Related]

  • 25. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
    Morrissey PE, Gohh R, Shaffer D, Crosson A, Madras PN, Sahyoun AI, Monaco AP.
    Transplantation; 1997 Mar 27; 63(6):845-8. PubMed ID: 9089224
    [Abstract] [Full Text] [Related]

  • 26. Detrimental effects of cyclosporin A on long-term graft survival in familial Mediterranean fever renal allograft recipients: experience of two transplantation centers.
    Shabtai M, Ben-Haim M, Zemer D, Malinger-Saavedra P, Rosin D, Kuriansky J, Lustig S, Shabtai EL, Shapira Z, Ayalon A.
    Isr Med Assoc J; 2002 Nov 27; 4(11 Suppl):935-9. PubMed ID: 12455184
    [Abstract] [Full Text] [Related]

  • 27. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.
    Herrero JI, Quiroga J, Sangro B, Girala M, Gómez-Manero N, Pardo F, Alvárez-Cienfuegos J, Prieto J.
    Liver Transpl Surg; 1999 Sep 27; 5(5):414-20. PubMed ID: 10477843
    [Abstract] [Full Text] [Related]

  • 28. Risk of acute cellular rejection after azathioprine withdrawal in stable renal allograft recipients on cyclosporine, azathioprine, and prednisone.
    Fabrega AJ, Roy G, Reynolds L, Corwin C, Hunsicker L.
    Transplant Proc; 1998 Jun 27; 30(4):1335-6. PubMed ID: 9636543
    [No Abstract] [Full Text] [Related]

  • 29. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation.
    Sarwal MM, Yorgin PD, Alexander S, Millan MT, Belson A, Belanger N, Granucci L, Major C, Costaglio C, Sanchez J, Orlandi P, Salvatierra O.
    Transplantation; 2001 Jul 15; 72(1):13-21. PubMed ID: 11468528
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Weaning of immunosuppression in living donor liver transplant recipients.
    Takatsuki M, Uemoto S, Inomata Y, Egawa H, Kiuchi T, Fujita S, Hayashi M, Kanematsu T, Tanaka K.
    Transplantation; 2001 Aug 15; 72(3):449-54. PubMed ID: 11502975
    [Abstract] [Full Text] [Related]

  • 37. Comparison of tacrolimus and cyclosporin in renal transplantation by the protocol biopsies.
    Töz H, Sen S, Seziş M, Duman S, Ozkahya M, Ozbek S, Hoşcoşkun C, Atabay G, Ok E.
    Transplant Proc; 2004 Aug 15; 36(1):134-6. PubMed ID: 15013324
    [Abstract] [Full Text] [Related]

  • 38. Steroid withdrawal is safe and beneficial in stable cyclosporine-treated liver transplant patients.
    Gómez R, Moreno E, Colina F, Loinaz C, Gonzalez-Pinto I, Lumbreras C, Perez-Cerdá F, Castellón C, García I.
    J Hepatol; 1998 Jan 15; 28(1):150-6. PubMed ID: 9537852
    [Abstract] [Full Text] [Related]

  • 39. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation.
    Fisher RA, Stone JJ, Wolfe LG, Rodgers CM, Anderson ML, Sterling RK, Shiffman ML, Luketic VA, Contos MJ, Mills AS, Ferreira-Gonzalez A, Posner MP.
    Clin Transplant; 2004 Aug 15; 18(4):463-72. PubMed ID: 15233827
    [Abstract] [Full Text] [Related]

  • 40. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation.
    Opelz G, Döhler B, Collaborative Transplant Study.
    Transplantation; 2009 Mar 27; 87(6):795-802. PubMed ID: 19300179
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 41.